Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors

Fenghui Zhao,Qingtong Zhou,Zhaotong Cong,Kaini Hang,Xinyu Zou,Chao Zhang,Yan Chen,Antao Dai,Anyi Liang,Qianqian Ming,Mu Wang,Li-Nan Chen,Peiyu Xu,Rulve Chang,Wenbo Feng,Tian Xia,Yan Zhang,Beili Wu,Dehua Yang,Lihua Zhao,H. Eric Xu,Ming-Wei Wang

DOI: https://doi.org/10.1038/s41467-022-28683-0

IF: 16.6

2022-02-25

Nature Communications

Abstract:Abstract Glucose homeostasis, regulated by glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) is critical to human health. Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity. To elucidate the molecular mechanisms by which tirzepatide, a GIPR/GLP-1R dual agonist, and peptide 20, a GIPR/GLP-1R/GCGR triagonist, manifest their multiplexed pharmacological actions over monoagonists such as semaglutide, we determine cryo-electron microscopy structures of tirzepatide-bound GIPR and GLP-1R as well as peptide 20-bound GIPR, GLP-1R and GCGR. The structures reveal both common and unique features for the dual and triple agonism by illustrating key interactions of clinical relevance at the near-atomic level. Retention of glucagon function is required to achieve such an advantage over GLP-1 monotherapy. Our findings provide valuable insights into the structural basis of functional versatility of tirzepatide and peptide 20.

multidisciplinary sciences